$10.21 0.00 (0.00%)

Janus International Group, Inc. (JBI)

Janus International Group, Inc. (JBI) is a global provider of innovative building solutions, primarily specializing in the manufacturing and installation of modular, portable, and re-locatable building systems. The company serves the self-storage, commercial, and industrial sectors, offering products such as storage doors, wall systems, and building infrastructure. Janus International focuses on delivering scalable, efficient, and sustainable building solutions to improve operational performance and customer experience.

🚫 Janus International Group, Inc. does not pay dividends

Company News

JBI INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Janus International Group, Inc. and Encourages Investors to Contact the Firm
GlobeNewswire Inc. • Bronstein, Gewirtz & Grossman, Llc • November 6, 2024

Janus International Group, Inc. reported a 17.9% year-over-year decline in revenue for its fiscal third quarter, missing consensus estimates by $18.11 million. The company also lowered its full-year revenue guidance, citing macroeconomic factors, interest rate uncertainty, and project delays.

Wall Street Analysts See a 26.46% Upside in Janus International Group (JBI): Can the Stock Really Move This High?
Zacks Investment Research • Zacks Equity Research • May 29, 2024

The consensus price target hints at a 26.5% upside potential for Janus International Group (JBI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Benzinga's Top Ratings Upgrades, Downgrades For July 24, 2023
Benzinga • Benzinga Insights • July 24, 2023

Upgrades Maxim Group upgraded the previous rating for Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) from Hold to Buy. For the first quarter, Galmed Pharmaceuticals had an EPS of $1.09, compared to year-ago quarter EPS of $3.60. The stock has a 52-week-high of $14.18 and a 52-week-low of $1.10. At the end of the last trading period, Galmed Pharmaceutic...

Masonite International Still Offers Upside From Here
Seeking Alpha • Daniel Jones • February 5, 2023

Masonite International has proven itself to be a quality business that has demonstrated robust growth. See why I've decided to keep the Buy rating for DOOR stock.

Why Janus International Group Stock Rallied 23% at the Open Today
The Motley Fool • [email protected] (Reuben Gregg Brewer) • May 17, 2022

The company's unique product portfolio appears to be paying off, with impressive top- and bottom-line gains in the first quarter.